InMode Ltd. (INMD) – What Are Analysts Saying About This Stock?

Shares of InMode Ltd. (NASDAQ:INMD) have been given a consensus recommendation of “Hold” by the six ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $16.00.

Separately, Weiss Ratings downgraded shares of InMode from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday.

InMode Trading Up 2.8%

NASDAQ:INMD opened at $14.08 on Friday. The firm has a market capitalization of $809.32 million, a PE ratio of 11.45 and a beta of 1.98. InMode has a 1 year low of $12.72 and a 1 year high of $16.67. The firm’s fifty day simple moving average is $14.33 and its 200 day simple moving average is $14.32.

InMode (NASDAQ:INMD) last released its earnings results on Wednesday, August 5th. The healthcare company reported $0.35 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.35. InMode had a net margin of 20.69% and a return on equity of 11.99%. The firm had revenue of $95.59 million during the quarter, compared to analyst estimates of $94.89 million. During the same quarter in the previous year, the business earned $0.47 EPS. The business’s revenue was up .0% on a year-over-year basis.

Institutional Trading of InMode

Institutional investors have recently made changes to their positions in the business. Steel Partners Holdings L.P. boosted its stake in InMode by 154.8% in the 1st quarter. Steel Partners Holdings L.P. now owns 1,795,361 shares of the healthcare company’s stock valued at $24,561,000 after buying an additional 1,090,697 shares in the last quarter. Renaissance Technologies LLC grew its position in InMode by 6.1% in the first quarter. Renaissance Technologies LLC now owns 2,586,218 shares of the healthcare company’s stock valued at $35,379,000 after acquiring an additional 149,800 shares during the period. CenterBook Partners LP bought a new stake in InMode in the third quarter valued at $1,866,000. Prospect Capital Advisors LLC raised its stake in InMode by 50.6% during the first quarter. Prospect Capital Advisors LLC now owns 313,450 shares of the healthcare company’s stock worth $4,288,000 after acquiring an additional 105,250 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in InMode during the second quarter worth $1,254,000. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Company Profile

InMode Ltd. (NASDAQ: INMD) is a global medical technology company that develops and commercializes energy-based platforms for aesthetic and medical treatments. Its systems are designed to support minimally invasive and noninvasive procedures performed by physicians and other healthcare professionals.

The company’s product portfolio includes platforms and handpieces used in facial and body contouring, skin resurfacing, skin tightening, hair removal, and women’s health applications. Its technologies include radio-frequency and other energy-based treatments, with products such as Morpheus8, BodyTite, FaceTite, Optimas, and EmpowerRF serving a range of clinical and aesthetic needs.

Founded in 2008, InMode sells its products through direct sales and distribution channels to medical practices, clinics, and other healthcare providers.